Background {#Sec1}
==========

Gastric cancer is one of the most commonly diagnosed cancers, and in both sexes combined the third leading cause of cancer-related deaths worldwide \[[@CR1], [@CR2]\]. Prominent differences in age-standardized incidence are observed in different parts of the world ranging from 32.1% in eastern Asia to 8,2% in Western Europe \[[@CR2]\]. Among sporadic (distal) gastric adenocarcinomas *Helicobacter pylori* infection remains the most important cause which can partly reflect the different incidence rates worldwide \[[@CR3], [@CR4]\].

In advanced tumor stages and especially in metastatic patients the overall survival is still poor with a median overall survival of less than 1 year in the latter \[[@CR5]\]. Therefore, molecular targets need to be identified providing further therapeutic options.

The only molecular alteration that is currently used therapeutically in gastric cancer is Her2/neu. The ToGa (Trastuzumab for Gastric Cancer) trial demonstrated improved overall survival in patients with Her2/neu amplified tumors who received trastuzumab in addition to standard chemotherapy in comparison to chemotherapy alone \[[@CR6]\]. Within primary tumors intratumoral heterogeneity has been demonstrated in up to 33% and between those and distant metastasis in 11% \[[@CR7]\]. Therefore, heterogeneity of gene amplifications within primary gastric adenocarcinomas is not uncommon.

The Cancer Genome Atlas research network (TCGA) has performed full genomic profiling of 259 primary gastric adenocarcinomas and reported four main molecular tumor subtypes: tumors positive for Epstein-Barr virus (EBV), microsatellite unstable tumors (MSI), genomically stable tumors (GS) and tumors with chromosomal instability (CIN) \[[@CR8]\].

While in the past the mutational status of *KRAS* was of great interest, recent studies focused on high-level amplification of *KRAS*. In several cancer entities amplification of *KRAS* has been reported and was associated with poor clinical outcome in most cases \[[@CR9], [@CR10]\]. Amplifications occurred mutually exclusive with mutations in *KRAS* and were also demonstrated to be activating with marked overexpression of KRAS protein \[[@CR8], [@CR11]\]. The extent of KRAS amplification is only known from large Asian patient populations. To what extent these results can be transferred to a Caucasian patient collective is still unclear. Recently, a study could show a possible individualized therapy option for *KRAS* amplified gastric cancer \[[@CR11]\].

In the present study we analyzed the tumor tissue of a large cohort of 582 Caucasian patients with gastric adenocarcinomas. We employed immunohistochemistry (IHC) and fluorescence in-situ hybridization (FISH) as sensitive and well established diagnostic tools to detect amplification and protein expression of *KRAS* and focused on its intratumoral heterogeneity. Amplification status was then correlated with clinico-pathological features, clinical outcome and molecular tumor data including a correlation to the TCGA subtypes of gastric carcinoma.

Methods {#Sec2}
=======

Statistical analysis {#Sec3}
--------------------

Patient data was prospectively abstracted into a database. Interdependences between staining, tumor characteristics and clinical data were compared with the use of Pearson's chi-squared test and Fisher's exact test and illustrated by cross-tables. Overall survival was evaluated from the date of surgery to death. Kaplan-Meier curves were generated and compared using the log-rank test. Data on patients with no event or lost follow up were censored at the last seen date. Multivariate analysis for prognostic factors was performed using the Cox regression model. A two-sided *p*-value \< 0.05 was considered statistically significant. SPSS package version 25 (IBM, Armonk, New York) was used for all statistical analyses.

Surgery {#Sec4}
-------

Standardized surgical treatment included subtotal distal or total gastrectomy extended with transhiatal resection of the oesophagus in case of an adenocarcinoma of the esophagogastric junction (Siewert 2 or 3), and a systematic D2 lymphadenectomy with the goal of complete resection (R0). Roux-en-Y jejunal loop obstruction with gastrojejunostomy was considered the method of choice in the reconstruction procedures. Patients with advanced gastric adenocarcinoma (cT3, cNx, M0) received either chemoradiation or chemotherapy.

Cohort {#Sec5}
------

Tumor samples of 582 patients with gastric adenocarcinoma were considered for analysis. According to the TCGA \[[@CR8]\] and the WHO classification of tumors (Digestive System Tumours, 5th edition, 2019) tumors were classified into four subgroups: (1) Those tumors positive for EBV (using EBER-ISH), (2) Tumors with MSI (using immunohistochemistry for MLH1, PMS2, MSH2, MSH6 and/or MSI testing), (3) Genomically stable tumors (GS) with poorly cohesive type morphology and/or *RHOA* mutations and/or E-cadherin loss, (4) Tumors with chromosomal instability (CIN) with intestinal type morphology and *HER2* amplification/overexpression and/or *TP53* mutations.

Tissue microarray (TMA) {#Sec6}
-----------------------

For TMA one tissue core from each tumor sample was punched out and transferred into a TMA recipient block. TMA construction was performed as previously described \[[@CR12], [@CR13]\]. In brief, tissue cylinders with a diameter of 1.2 mm each were punched from selected tumor tissue blocks using a self-constructed semi-automated precision instrument and embedded in empty recipient paraffin blocks.

Immunohistochemistry {#Sec7}
--------------------

Immunohistochemistry (IHC) was performed on TMA slides. The KRAS antibody (mouse monoclonal primary antibody, clone 9.13, Thermo Fisher) was stained on the automated Ventana/Benchmark slide stainer. Expression of KRAS in the cytoplasm of carcinoma cells was assessed according to the following criteria: negative or weak staining in \< 5% of tumor cells (score 0); weak staining ≥5--20% of tumor cells (score 1); moderate to strong staining in ≥20% (score 2). The evaluation of immunohistochemical expression was assessed manually by two pathologists (A.Q. and J.R.). Discrepant results, which occurred only in a small number of samples, were resolved by consensus review.

Fluorescence in-situ hybridization (FISH) {#Sec8}
-----------------------------------------

Fluorescence in-situ hybridization (FISH) for the evaluation of the *KRAS* gene amplification status was performed on TMA and large scale slides with the Zytolight SPEC KRAS/CEN 12 Dual Color Probe (Zytomed, Systems GmbH, Germany) according to the manufacturers' protocol. Sample processing was performed as previously described \[[@CR14]\]. Tumor tissue was scanned for amplification spots and heterogeneity using a 63x objective (DM5500 fluorescent microscope; Leica). Samples were evaluated as "*KRAS* amplified" with a ratio greater than 3 between *KRAS* gene and chromosome 12 centromere signals following previous studies \[[@CR15]\].

Results {#Sec9}
=======

Clinico-pathological and patient characteristics {#Sec10}
------------------------------------------------

The entire patient cohort consisting of 582 patients with gastric adenocarcinoma were considered for analysis. In total there were 470 analysable cases for *KRAS* (80.8%) on the TMA (Table [1](#Tab1){ref-type="table"}). Reasons for missing data included the lack of tissue samples or the absence of unequivocal cancer tissue on the TMA spot. Neoadjuvant treatment consisting of either chemo-radiation or chemotherapy was administered in 198 patients (35.4%). The median follow-up for patients still alive was 26 months with a calculated 5-year survival rate of 38.4%. Table 1*KRAS* amplification and clinico-pathological characteristics*KRAS* amplificationtotal (*n* = 470)negative (*n* = 443)positive (*n* = 27)n%n%n%*p*-valuesexmale29562.8%27558.5%204.3%0.528female14530.9%13829.4%71.5%n.a.306.4%306.4%00.0%agegroup\< 50428.9%418.7%10.2%0.339\> 5033170.4%30564.9%265.5%not available9720.6%9720.6%00.0%tumor stageT16513.8%6213.2%30.6%0.830T214731.3%13628.9%112.3%T316635.3%15733.4%91.9%T46714.3%6313.4%40.9%not available255.3%255.3%00.0%nodal stageN016535.1%16034.0%51.1%0.024N110522.3%10021.3%51.1%N27816.6%7115.1%71.5%N37616.2%6614.0%102.1%not available469.8%469.8%00.0%localisationproximal20543.6%18639.6%194.0%0.092body7014.9%6914.7%10.2%distal9820.9%9119.4%71.5%not available9720.6%9720.6%00.0%

*KRAS* amplification {#Sec11}
--------------------

*KRAS* amplifications were observed in 27 patients (5.7%) (for example see Fig. [1](#Fig1){ref-type="fig"}). The amplification profile for *KRAS* was not affected by the administration of neoadjuvant treatment. Within the group of patients undergoing primary surgery and the group of patients receiving neoadjuvant treatment first, 18 (6.0%) and 9 (6.3%) patients showed *KRAS* amplification respectively (*p* = 0.826). *KRAS* amplifications were not associated with sex (*p* = 0.528), age group (*p* = 0.339), tumor stage (*p* = 0.830) and localisation (a tendency toward proximal localization can be found) (*p* = 0.092). Nodal positive patients (pN+) were significantly correlated with a higher frequency of *KRAS* amplification (*p* = 0.024) (Table [1](#Tab1){ref-type="table"}). Fig. 1Primary gastric adenocarcinoma with *KRAS* amplification (*KRAS* FISH, 63x). Green cluster signals: *KRAS* locus (=amplification). Red signals: Centromer region of chromosome 12

The analysis of *KRAS* amplification in relation to the molecular classification of gastric adenocarcinoma (according to TCGA) revealed that 24 (88.8%) were related to tumors with chromosomal instability (CIN) and 3 (11.1%) were related to genomically stable (GS) tumors (*p* = 0.282) (Table [2](#Tab2){ref-type="table"}). No EBV or MSI-related gastric tumors harboured *KRAS* amplification. Table 2*KRAS* amplification and molecular subtype according to TCGA. CIN (chromsomal instable tumors); GN (genomically stable tumors); MSI (microsatellite instable tumors); EBV (Epstein-Barr virus-related tumors)*KRAS* amplificationtotal (*n* = 470)negative (*n* = 443)positive (*n* = 27)*p*-valueTCGACIN35074.5%32673.6%2488.9%0.282GN5812.3%5512.4%311.1%MSI367.7%368.1%00.0%EBV245.1%245.4%00.0%not available20.4%20.5%00.0%

*KRAS* and prognosis {#Sec12}
--------------------

The survival analysis of the entire patient cohort did not show any difference in overall survival in dependence on the *KRAS* status (*p* = 0.212). However, a significant survival difference with a worse outcome for patients with *KRAS* amplification was identified when analysing patients without a neoadjuvant pre-treatment (primary resected). The median overall survival (OS) for *KRAS* wild-type patients was 35 months (95% CI: 19.2--50.8 months) compared to 16 months (95% CI: 0--46.36 months) for *KRAS* amplified patients (*p* = 0.032) (Fig. [2](#Fig2){ref-type="fig"}). Fig. 2Kaplan-Meier survival analysis comparing patients with *KRAS* amplified gastric adenocarcinomas (red lines) and patients without *KRAS* amplified gastric adenocarcinomas (blue lines). **a** Whole patient cohort including neoadjuvant and primary-resected tumors (*n* = 347). *KRAS* amplified gastric adenocarcinomas (red line; *n* = 23) and adenocarcinomas without *KRAS* amplification (blue line; *n* = 324). **b** Patients without neoadjuvant pretreatment (primary resected tumors) with *KRAS* amplified tumors (red line; *n* = 16) in comparison to patients without *KRAS* amplified tumors (blue line; *n* = 229). *KRAS* amplified tumors in the primary resected cohort show a statistically significant worse prognosis in comparison to non-*KRAS* amplified tumors (*p* = 0.032). **c** Patients with preoperative neoadjuvant treatment with *KRAS* amplified tumos (red line; *n* = 7) in comparison to patients without *KRAS* amplified tumors (*n* = 94; blue line)

A multivariate cox proportional hazard model revealed that *KRAS* amplifications cannot be considered as an independent prognostic marker. The poor prognosis is driven by an accumulation of lympho-nodal metastatic patients.

*KRAS* and heterogeneity {#Sec13}
------------------------

Gastric adenocarcinomas showed a varying homogeneity of *KRAS* amplified tumor clones within the tumor. *KRAS* amplified clones were found next to *KRAS* non-amplified tumor cell populations (see Fig. [3](#Fig3){ref-type="fig"}). All tumors amplified on TMA slides either representing primary tumors or metastasis were also analyzed on large scale slides. Heterogeneity was observed in 14 of 27 (51.9%) amplified tumors taking together heterogeneity within the primary tumor and those 3 cases with only *KRAS* amplified metastasis. In six cases (out of 14 *KRAS* amplified tumors with lymph node metastases) we could detect *KRAS* amplification in regional lymph node metastases but not in the primary available parts of the gastric tumor on TMA. We then analyzed further tumor parts of the stomach on large scale slides and were finally able to secure *KRAS* amplified clones in the primary tumor in three of the six cases (see discussion). Conversely, a primary tumor with *KRAS* amplification was found which was not found in regional lymph node metastases. The analyzed large scale of the primary tumor revealed a heterogenous distribution of *KRAS* amplified tumor cells in this case. The remaining 13 of 27 cases showed a homogeneous distribution of *KRAS* amplified carcinoma cells. Fig. 3Intratumoral heterogeneity of *KRAS* amplification (*KRAS* FISH, 63x). Left: Green cluster signals: *KRAS* locus (=amplification). Red signals: Centromer region of chromosome 12. Right: nuclear counterstaining with DAPI

*KRAS* amplification and KRAS protein expression {#Sec14}
------------------------------------------------

All tumors that harbored *KRAS* amplification detected by FISH analysis also expressed KRAS protein visualized by immunohistochemistry (Fig. [4](#Fig4){ref-type="fig"}). In 37 of 136 (27.2%) analyzed *KRAS* non-amplified tumor samples KRAS protein expression was observed. Fig. 4HE- and KRAS (IHC) staining in primary gastric adenocarcinomas. Left side: tumor sample with *KRAS* amplification. Right side: tumor sample without *KRAS* amplification

Discussion {#Sec15}
==========

Few studies exist that consider the importance of *KRAS* amplifications in gastric carcinoma \[[@CR11], [@CR16]\]. These studies, which analyzed Asian patient groups, showed, among other things, that *KRAS* amplification occurs largely mutation-exclusive and only in exceptional cases with simultaneous activating mutations of *KRAS*. These data are consistent with the results reported by the TCGA \[[@CR8]\].

The *KRAS* amplification leads to an expression enhancement of the KRAS protein and to an activation of downstream partners (e.g. RAF, MEK). In addition, several studies reported for different cancer entities that *KRAS* amplified tumors are associated with poor prognosis \[[@CR9], [@CR10]\].

Nothing is known about the intratumoral heterogeneity of *KRAS* amplification in gastric adenocarcinomas and its importance and prognostic relevance in a large Caucasian patient population. Asian and Non-Asian patient populations differ in various aspects such as risk profiles of tumorigenesis, metabolic and genomic differences \[[@CR17], [@CR18]\].

In comparison to the TCGA data we found a slightly lower amplification frequency of *KRAS* in our collection of 582 patients (5.8% vs. 7.1%). We confirm the statistically significant unfavorable prognosis of *KRAS* amplified tumors in cases of primarily resected, non-neoadjuvantly treated tumors. We no longer see this prognostic effect in the group of neoadjuvantly treated and secondarily operated patients.

It is well documented that the group of so-called "minor responders" to a neoadjuvant therapy (= more than 10% vital tumor residual in the surgical specimens) has a significantly worse prognosis than the group of "complete responders" (= no vital tumor remnant) \[[@CR19], [@CR20]\]. Therefore, it is worth noting that in this subgroup only tumor tissue of "minor responders" was analyzable.

We explain our findings by the already poor overall prognosis of the patient cohort that cannot be further degraded measurably by the amplification of *KRAS*.

Nothing is known about the possible intratumoral heterogeneity of *KRAS* amplified tumor cell clones in gastric adenocarcinoma. This work demonstrates the relevance of the heterogeneity of *KRAS* amplified tumor clones in gastric carcinoma for the first time. This is particularly possible with the method used (FISH). In six cases we found *KRAS* amplification only in regional lymph node metastases, but not in the corresponding tissue of the primary tumor represented in the TMA. In three cases we were able to detect small *KRAS* amplified tumor cell populations in the primary tumor on additionally analyzed large scale slides of the primary tumor. This can be interpreted that *KRAS* amplified tumor clones show a special affinity for lymphogenic metastasis. This is underlined by the unfavourable prognostic relevance of *KRAS* amplification. In the three cases in which we were not able to detect a *KRAS* amplified tumor clone in the primary tumor (but with the detection of regional, *KRAS* amplified lymph node metastases), we assume that we could not find this clone because we did not have the entire primary tumor tissue but only parts for analysis. We consider the alternative that *KRAS* amplification only manifest itself in the course of lymph node metastasis to be unlikely.

Intratumoral heterogeneity of *KRAS* amplification should be taken into consideration for possible future therapeutic interventions on *KRAS*-amplified tumors and could be an argument for a re-determination of the amplification-status of the metastasis if the analyzable primary tumor fraction did not show any amplification (for example in a biopsy involving only small proportions of the tumor).

We also investigated the extent to which *KRAS* amplification correlates with the expression of the protein. All amplified tumors also show a corresponding protein expression. Therefore we confirm the results of other studies \[[@CR11], [@CR16]\]. KRAS protein expression was also observed in *KRAS* non-amplified tumors. Therefore KRAS immunohistochemistry is not suitable to screen for *KRAS* amplification.

According to the results of TCGA, gastric carcinomas can be divided into four major molecular subtypes, as outlined in the introduction. In our collection of tumors we find a divergent composition (see Table [2](#Tab2){ref-type="table"}). However, in agreement with a previous publication \[[@CR11]\], we found a marked accumulation of *KRAS* amplified tumors in the group of so-called chromosomal instable tumors (CIN) in almost 90%. No single microsatellite-unstable or EBV-associated carcinoma also shows *KRAS* amplification. The enrichment of *KRAS* amplified tumors in the CIN subgroup is consistent, as it also has increased gene amplifications such as *FGFR2* or *ERBB2*. We found a single tumor with a co-amplification of *ERBB2* and *KRAS*.

For esophageal and gastric adenocarcinomas it has been reported that high-level amplifications of *KRAS* resulted in a relevant copy number increase of the wild-type *KRAS* gene in the absence of coding mutations. This leads to an increased expression of KRAS protein with downstream activation, that can be influenced therapeutically \[[@CR11], [@CR21]--[@CR23]\].

Our study has some limitations. This retrospective analysis only included tumor tissue from a single tumor center. We cannot make any reliable statements on the status of the primary tumor in the group of neoadjuvant treated patients. In this patient cohort, we only considered an accumulation of minor responders for neoadjuvant therapy, as in the group of complete responders no tumor material is available for analysis.

Conclusion {#Sec16}
==========

In summary, we present the importance of *KRAS* amplification in gastric carcinoma in a large cohort of 582 Caucasian patients. While activating *KRAS* mutations are well characterized in various carcinomas, there is little reliable data on the relevance of *KRAS* amplification in gastric carcinoma. We confirm the unfavorable prognosis of *KRAS* amplified tumors reported by other studies for (Asian) patient groups. This study reveals intratumoral heterogeneity of *KRAS* amplification and demonstrates the correlation of gene amplification and protein expression. Despite the heterogeneous distribution of *KRAS* amplified tumor clones, *KRAS* amplified gastric adenocarcinomas represent a therapeutically highly interesting tumor subgroup.

Future prospective analyzes are necessary, which not only consider the usual *KRAS* mutations but also *KRAS* amplifications.
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